Evidence map›Paper›PMID 31968535›Full record

ArticleInternational journal of molecular sciences2020

Metalloporphyrin Pd(T4) Exhibits Oncolytic Activity and Cumulative Effects with 5-ALA Photodynamic Treatment against C918 Cells.

Brandon Leviskas, Tibor Valyi-Nagy, Gnanasekar Munirathinam, Matthew Bork, Klara Valyi-Nagy, Troy Skwor

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Brandon LeviskasDepartment of Chemical and Biological Sciences, Rockford University, Rockford, IL 61107, USA.
Tibor Valyi-NagyDepartment of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Gnanasekar MunirathinamDepartment of Biomedical Sciences, College of Medicine at Rockford, University of Illinois, Rockford, IL 61108, USA.
Matthew BorkDepartment of Chemical and Biological Sciences, Rockford University, Rockford, IL 61107, USA.
Klara Valyi-NagyDepartment of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Troy SkworDepartment of Chemical and Biological Sciences, Rockford University, Rockford, IL 61107, USA.
Rockford University · USUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy is a non-invasive method where light activates a photosensitizer bound to cancer cells, generating reactive oxygen species and resulting in cell death. This study assessed the oncolytic potential of photodynamic therapy, comparing European Medicines Agency and United States Food and Drug Administration-approved 5-aminolevulinic acid (5-ALA) to a metalloporphyrin, Pd(T4), against a highly invasive uveal melanoma cell line (C918) in two- and three-dimensional models

Indexed as

PhotochemotherapyAminolevulinic AcidAntineoplastic AgentsApoptosisbcl-2-Associated X ProteinCell Line, TumorCell SurvivalGene Expression Regulation, NeoplasticHumansLightMelanomaMetalloporphyrinsNecrosisPhotosensitizing AgentsProto-Oncogene Proteins c-bcl-2Reactive Oxygen SpeciesAminolevulinic AcidAntineoplastic AgentsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanMetalloporphyrinsPhotosensitizing AgentsProto-Oncogene Proteins c-bcl-2Reactive Oxygen Species5-ALAapoptosisblue lightmelanomanecrosisPd(T4)reactive oxygen species

Identifiers

PMID31968535
PMCPMC7013453
OpenAlexW2999582433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.